MASLD, Obesity, Cardiometabolic Syndrome, T2DM are all overlapping yet distinct diseases. Follow a patient in real time from primary to tertiary care. Challenge the experts in hepatology, cardiology and obesity medicine as they debate the latest research and missed opportunities along the patient’s journey: Juggle polypharmacy, lifestyle interventions, biomarkers, multimodal imaging. Interactive Evening Symposium. Dinner and Refreshments provided.
Evaluate current evidence-base and accessibility for non-invasive tests (NITs) in the screening, diagnosis, monitoring and prognostication of patients at risk of or living with cardiometabolic syndrome and/or MASLD.
Compare and contrast beneficial and harmful effects and interactions between emerging pharmacotherapies in MASLD and cardiometabolic syndrome in order to tailor to patients needs.
Design MDT pathways and define the role of the hepatology practitioner when managing patients with multi-organ involvement at risk of or living with cardiometabolic syndrome and MASLD.